73 results about "Chemotherapy effects" patented technology

The invention provides application of a PDLIM4 gene in preparation of a medicine for inhibiting non-small cell lung cancer proliferation, belongs to the technical field of cancer suppressor gene research, and finds that the PDLIM4 gene is highly expressed in non-small cell lung cancer tumors, and the prognosis of a patient with the highly expressed PDLIM4 gene is good; the proliferation of the non-small cell lung cancer cells overexpressed with the PDLIM4 gene is inhibited, and the proliferation of the non-small cell lung cancer cells knocked down with the PDLIM4 gene is accelerated, so that the reagent capable of realizing the overexpression of the PDLIM4 gene is confirmed to be of great significance for inhibiting the proliferation of the non-small cell lung cancer cells. The overexpression of the PDLIM4 gene in the non-small cell lung cancer cells can enhance the chemotherapy effect of the chemotherapy drug adriamycin, and can be used as a chemotherapy sensitizer. The BRD4 is an upstream regulatory factor for increasing the expression of the PDLIM4 gene in the non-small cell lung cancer, and can be used for promoting the expression of the PDLIM4 gene.

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

A method of predicting an effect of a chemotherapy treatment on a cancer patient's cognitive status using the patient's predicted age difference (PAD) comprises acquiring at least one medical brain image of a patient's brain before a chemotherapy treatment; processing the medical brain image to obtain at least one feature of the image; generating a PAD value of the individual based on the at least one feature of the image; and predicting an effect of the chemotherapy treatment on a cancer patient's cognitive status using the PAD value.

The invention discloses an EGFR (epidermal growth factor receptor) targeted nano-drug carrier and a preparation method thereof, the EGFR targeted nano-drug carrier comprises drug-loading nanoparticles, an erythrocyte membrane coating the drug-loading nanoparticles and GE11 peptide connected to the erythrocyte membrane, and the drug-loading nanoparticles are formed by connecting tannic acid, ellagic acid and 1, 4-phenyldiboronic acid through boric acid ester bonds. The EGFR targeted nano-drug carrier disclosed by the invention can be enriched at an EGFR overexpressed tumor site in a targeted manner, and can be effectively prevented from being cleared by an immune system, and the drug loaded by the drug-loaded nanoparticles is released in a high-active oxygen environment, so that the treatment effect on tumors can be improved, and the toxic and side effects on normal tissues can be reduced; and photothermal therapy and chemotherapy effects can be simultaneously generated under NIR illumination, and the anticancer efficiency can be remarkably improved through the synergistic effect of the photothermal therapy and the chemotherapy.

The invention relates to the technical field of nano medicine, in particular to iron gambogic acid adriamycin nano particles, a preparation method and application. Gambogic acid, doxorubicin hydrochloride and an iron-containing compound are matched, carbonyl oxygen and hydroxyl in the gambogic acid and Fe < 3 + > form coordinate bonds, carbonyl and amino in the doxorubicin hydrochloride and a conjugated system in a benzene ring are combined with Fe < 3 + > through covalent bonds and pi-pi accumulation, a core-shell structure is formed, and the iron gambogic acid doxorubicin nano-particles are obtained. The particle size of the iron gambogic acid adriamycin nano-particles ranges from 2 nm to 10 nm. The iron gambogic acid adriamycin nano-particles have excellent multi-enzyme activity, autophagy amplification is effectively achieved, traditional chemotherapy drug resistance caused by autophagy is overcome, and the glioma chemotherapy effect is improved.

The invention discloses a multifunctional tumor targeted low-temperature treatment nano platform and application thereof, and belongs to the technical field of nano biological medicines. According to the multifunctional tumor targeted low-temperature treatment nano platform, the two-dimensional Ti3C2 nano material serves as a carrier, indocyanine green is loaded to serve as a photosensitizer, polydopamine is modified on the surface to improve the stability, and gambogic acid is loaded to serve as an anti-tumor drug and a heat shock protein inhibitor; and a nucleic acid aptamer capable of recognizing specific protein on the cell surface is coupled in a covalent binding manner. The multifunctional tumor targeted low-temperature treatment nano platform is small in particle size, high in dispersion degree and good in biocompatibility, and shows excellent photo-thermal conversion capacity, photodynamic treatment effect and chemotherapy effect in tumor targeted treatment. The apoptosis of tumor cells can be effectively induced under a relatively low temperature condition, and the damage of high temperature to surrounding healthy tissues is remarkably reduced. The tumor focus specific recognition capability is also realized, the high enrichment at the tumor part can be realized, and the treatment effect is enhanced.

The invention discloses a graphene quantum dot material as well as a preparation method and application thereof, and belongs to the technical field of biomedical materials. The preparation method comprises the following steps: S1, carrying out hydrothermal reaction on a mixed solution of mesoporous SiO2 and a carbon source to obtain a product I; s2, the product I and a fluoride solution are mixed to remove SiO2, and a product II is obtained; and S3, refining the product II to obtain the graphene quantum dot material. The carbon source is selected from at least one of triammonium citrate, diammonium hydrogen citrate, citric acid, folic acid, urea, thiourea and dicyanodiamine; the fluoride is selected from ammonium bifluoride and / or hydrogen fluoride. The particle size of the graphene quantum dot material provided by the invention is 15-30nm, the distribution is controllable, and the raw materials are easy to obtain; the prepared platinum nanoparticle / graphene quantum dot composite nanomaterial is high in solubility, stable in physical and chemical properties and remarkable in chemotherapy effect.

The invention discloses a grifola frondosa-derived exosome-like nano-vesicle as well as an extraction method and application thereof. The extraction method comprises the following steps: cutting pilei and stipes of grifola frondosa, and grinding with a proper amount of cold PBS to prepare grifola frondosa bacterial juice; the grifola frondosa juice is centrifuged at 500 g-1, 000 g, sediment is discarded, the obtained supernatant is centrifuged at 2,000 g-3,000 g, sediment is discarded, the obtained supernatant is centrifuged at 10,000 g-12,000 g, sediment is discarded, the obtained supernatant is filtered, and the pretreated grifola frondosa juice is obtained; and centrifuging the pretreated grifola frondosa juice at 30,000-100,000 g for 30 minutes to 4 hours, and resuspending by using PBS (Phosphate Buffer Solution), so as to obtain the grifola frondosa-derived exosome-like nano-vesicles. The invention develops a new thought for the mechanism of cancer inhibition, chemotherapy effect enhancement and flora regulation of the grifola frondosa, and lays a foundation for application of the grifola frondosa in development of products such as related foods, functional foods, health foods, medicines and gel-loaded medicines.

The invention discloses a clinical chemotherapy curative effect prediction and analysis method based on a multi-center MRI image interpretable model, and relates to the technical field of medical image analysis, and the method is characterized in that an MRI image of a patient is collected, the MRI image is screened and preprocessed, radiomics characteristics are extracted, and a clinical chemotherapy curative effect prediction and analysis result is obtained. On the basis of an intra-group correlation coefficient ICC, Mann-Whitney U test, Spearman correlation analysis and an elastic network regression algorithm, nasopharynx cancer radiomics characteristics are screened out from the radiomics characteristics to construct a GNN neural network model so as to predict the induced chemotherapy reaction of the patient with the local advanced nasopharynx cancer. The core problem that the curative effect of a patient with local advanced nasopharyngeal carcinoma cannot be accurately predicted before induced chemotherapy at present is solved, and chemotherapy injury and excessive treatment caused by induced chemotherapy are effectively avoided.

The invention provides a traditional Chinese medicine preparation for preventing and treating myelosuppression after chemotherapy, and relates to the field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is prepared from 1-15 parts of deer-horn glue, 1-10 parts of astragalus membranaceus, 1-10 parts of cassia twig, 1-10 parts of pseudo-ginseng, 1-10 parts of immature bitter orange, 1-10 parts of rhizoma anemarrhenae and 1-10 parts of golden cypress, and the traditional Chinese medicine preparation has the effects of invigorating qi and blood, promoting blood circulation to remove blood stasis, relieving swelling and pain and the like. The traditional Chinese medicine preparation disclosed by the invention can reverse myelosuppression caused by 5-FU chemotherapy by improving the peripheral hemogram of a chemotherapy mouse and pathological injury of bone marrow. In addition, the traditional Chinese medicine preparation can improve the 5-FU chemotherapy effect by increasing the 5-FU tumor inhibition rate, inhibiting tumor weight and tumor volume and promoting tumor tissue necrosis. The traditional Chinese medicine preparation disclosed by the invention is combined with a chemotherapeutic drug 5-FU for application, has certain effects of enhancing effects and reducing toxicity, and is expected to be developed into a drug for preventing and treating myelosuppression after chemotherapy.

The invention relates to a hybrid nano assembly for dual synergistic chemotherapy as well as a preparation method and application of the hybrid nano assembly, and belongs to the technical field of pharmaceutical preparations. The invention relates to a hybrid nano assembly for dual synergistic chemotherapy, which is formed by co-assembling a cabazitaxel prodrug and gossypol under hydrophobic action and hydrogen bond driving, and is modified by adopting a PEG (Polyethylene Glycol) modifier, the molar ratio of the cabazitaxel prodrug to the gossypol is 1: (1-7), and the ratio of the total mass of the cabazitaxel prodrug and the gossypol to the mass of the PEG modifier is 4: 1. A cabazitaxel prodrug and a sensitizer gossypol are co-assembled to obtain a hybrid nano assembly, the hybrid nano assembly is oxygenated to obtain the oxygen-carrying preparation, the nano assembly and the oxygen-carrying preparation are simple and convenient to prepare and high in drug loading efficiency, and efficient co-loading of drugs can be achieved; meanwhile, the curative effect of chemotherapy can be enhanced through dual mechanisms of relieving tumor hypoxia and promoting tumor apoptosis, and the pharmaceutical composition has a good clinical application prospect.

The invention discloses a nano preparation for natural product synergistic chemotherapy as well as a preparation method and application of the nano preparation, nanoparticles are formed by self-assembly of an SN38 prodrug sensitive to redox and galangin in a carrier-free manner, and can also be co-assembled nanoparticles modified by polyethylene glycol or entrapped with hydrophobic fluorescent molecules. According to the SN38 prodrug, a fluorene methanol side chain is coupled to an SN38 molecule through a redox-sensitive disulfide bond, so that a prodrug structure with a responsive release characteristic is constructed. The construction of the nano system not only significantly reduces the off-target toxicity of SN38 and improves the tolerance dose of SN38, but also enhances the SN38-mediated chemotherapy effect by the sensibilization effect of galangin, significantly improves the treatment efficiency, and realizes high-efficiency and low-toxicity cancer treatment. The invention provides a novel and synergistic prodrug nano drug delivery platform, and a new strategy is provided for precise treatment of refractory tumors.

This invention discloses a multifunctional tumor-targeted cryotherapy nanoplatform and its applications, belonging to the field of nanobiomedicine technology. The multifunctional tumor-targeted cryotherapy nanoplatform of this invention uses two-dimensional Ti3C2 nanomaterials as a carrier, loaded with indocyanine green as a photosensitizer, surface-modified with polydopamine to improve stability, and loaded with gambogeylic acid as an anti-tumor drug and a heat shock protein inhibitor. It is covalently coupled with nucleic acid aptamers that can recognize cell surface-specific proteins. The multifunctional tumor-targeted cryotherapy nanoplatform has small particle size, high dispersion, and good biocompatibility, and exhibits excellent photothermal conversion ability, photodynamic therapy effect, and chemotherapy effect in tumor-targeted therapy. It can effectively induce tumor cell apoptosis under relatively low temperature conditions, significantly reducing the damage of high temperature to surrounding healthy tissues. It also has the ability to specifically recognize tumor lesions, achieving high enrichment at the tumor site and enhancing the therapeutic effect.

The application discloses Lactobacillus reuteri and application thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, and relates to the technical field of biological medicine. The application provides application of Lactobacillus reuteri and / or a metabolite thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, wherein the Lactobacillus reuteri is Lactobacillus reuteri (HG001). Limosilactobacillus reuteri The Lactobacillus reuteri is separated from feces of healthy people and used for preparation of the medicine for treating diffuse large B-cell lymphoma, and it is found that the Lactobacillus reuteri is confirmed as a probiotic strain for enhancing the chemotherapy effect of diffuse large B-cell lymphoma and can improve side effects caused by cyclophosphamide treatment of diffuse large B-cell lymphoma; and the Lactobacillus reuteri and the cyclophosphamide have a synergistic effect in treatment of diffuse large B-cell lymphoma.

The invention relates to the technical field of biological medicines, and particularly discloses a high-grade serous ovarian cancer (HGSOC) treatment strategy based on ANXA6 protein detection and regulation. The invention provides a method for evaluating the sensitivity of a patient to cisplatin chemotherapy by detecting the expression level of ANXA6 protein or a specific modification site thereof, and a composition comprising inhibiting the function of ANXA6 or combining with cisplatin. In addition, the invention also relates to a medicine application for enhancing the chemotherapy effect by regulating the activity of ANXA6 related modifying enzyme.

The invention belongs to the technical field of medical biology, and particularly relates to novel application of GPRC5A which serves as a novel molecular target point GPRC5A for overcoming pancreatic cancer chemotherapy drug resistance, so that the problems that in the prior art, the chemotherapy effect of pancreatic cancer patients is poor, and chemotherapy drug resistance is likely to be generated are solved, the curative effect of a classical chemotherapy regimen is improved, and the long-term survival rate of the pancreatic cancer patients is increased.

The application discloses a polymer vesicle-stabilized drug-iodized oil emulsion and a preparation method and application thereof, to realize safe and efficient transarterial chemoembolization (TACE) treatment of hepatocellular carcinoma in situ. The drug-iodized oil emulsion system has the following advantages: simple preparation, convenient size adjustment, excellent stability, near-zero order and sustained controllable drug release rate, low blood drug concentration after transarterial embolization, and the retention time and retention amount of the drug in the liver are superior to those of free drug-iodized oil emulsion used in clinical treatment, the tumor can be completely eradicated, angiogenesis can be effectively inhibited, and adverse reactions can be reduced. In general, the polymer vesicle-stabilized drug-iodized oil emulsion has the advantages of high stability and sustained controllable drug release, and can greatly improve the embolization chemotherapy effect of hepatocellular carcinoma, and provide a safe and efficient TACE strategy.

The present invention provides a kind of Chinese medicine preparation for preventing and treating myelosuppression after chemotherapy, relates to the field of Chinese medicine pharmacy, the Chinese medicine preparation is made of 1-15 parts of antler glue, 1-10 parts of astragalus, 1-10 parts of cinnamon twig, 1-10 parts of notoginseng, 1-10 parts of immature bitter orange, 1-10 parts of rhizoma anemarrhenae, 1-10 parts of phellodendron, and the Chinese medicine preparation of the present invention has the effects such as replenishing qi and blood, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain. The Chinese medicine preparation of the present invention can reverse the myelosuppression caused by 5-FU chemotherapy by improving the peripheral blood count and bone marrow pathological damage of chemotherapy mice. In addition, the Chinese medicine preparation of the present invention can improve the 5-FU chemotherapy effect by increasing the 5-FU tumor inhibition rate, suppressing tumor weight, tumor volume and promoting tumor tissue necrosis. The Chinese medicine preparation of the present invention and the chemotherapy drug 5-FU are used in combination to have a certain synergistic and toxicity-reducing effect, and are expected to be developed as a medicine for preventing and treating myelosuppression after chemotherapy.

The invention belongs to the technical field of biological medicine, and particularly relates to application of REXO4 interference polypeptide in tumor treatment. It is found for the first time that the REXO4 interference polypeptide can inhibit breast cancer tumor cell proliferation, promote chemotherapy drug-induced DNA damage and improve the breast cancer chemotherapy effect, in addition, through combination of the REXO4 interference polypeptide and Olaparib, the remarkable synergistic anti-tumor effect can be shown, and the effect is better than that of single medication. The invention also finds that the REXO4 interference polypeptide can reverse the drug resistance of breast cancer to chemotherapeutic drugs, and a brand new solution is provided for overcoming the drug resistance of PARP inhibitors.

The utility model discloses a tumor local thermochemotherapy device which comprises a support and a thermochemotherapy device body, the thermochemotherapy device body is fixedly connected to the front end of the support, the front end of the support is fixedly connected with a connecting plate, the front end of the connecting plate is movably connected with a connecting column, the outer side of the connecting column is movably connected with two sets of fixing clamps, and the fixing clamps are fixedly connected with the support. And the two groups of fixing clamps are mutually symmetrical. According to the tumor local thermochemotherapy device, the chemotherapy device can be conveniently transferred, and meanwhile, the chemotherapy device can be fixed to a sickbed, so that the situation that the chemotherapy effect is affected due to deviation in the chemotherapy process is avoided.

The present invention belongs to the field of pharmaceutical chemistry technology, and specifically relates to a near-infrared light-releasing binuclear ruthenium complex, its preparation, and its application in combating drug resistance in non-small cell lung cancer. The binuclear ruthenium complex disclosed in the present invention has the structural formula shown below. The complex has a strong photochemotherapy effect on cisplatin-resistant human non-small cell lung cancer cell lines. Under light conditions, it has a strong growth and proliferation inhibition ability (IC 50 The phototoxicity of the metallo-photosensitive material was 0.22 μM, while in the dark, its cytotoxicity was only 75.6 μM, and the phototherapy index (PI) was as high as 343, which is of great significance for the study of metallo-medicines for anti-drug-resistant tumors. It is expected to be used to prepare anti-tumor photoactivated drugs or drugs for anti-proliferation of cisplatin-resistant strains of human non-small cell lung cancer, and even anti-tumor metal photosensitizers.

The invention provides a pharmaceutical composition and application thereof in preparation of medicines for treating ovarian cancer, and the pharmaceutical composition is prepared from the following components in parts by weight: 5-20 parts of cortex phellodendri, 5-20 parts of rhizoma atractylodis, 5-20 parts of radix achyranthis bidentatae, 5-20 parts of oldenlandia diffusa, 5-20 parts of radix trichosanthis, 5-20 parts of cassia twig, 20-40 parts of radix astragali and 20-40 parts of semen coicis. The pharmaceutical composition provided by the invention is suitable for ovarian cancer postoperative combined chemotherapy, and can significantly reduce the incidence rate of adverse reactions of chemotherapy, improve the chemotherapy effect and compliance, and reduce the toxic and side effects of chemotherapy drugs.

The invention belongs to the technical field of blood disease diagnosis, and provides a noninvasive screening method for acute B lymphocytic leukemia (B-ALL) based on a peripheral blood CD3 + CD19 + double positive cell subset, which comprises the following steps: detecting the proportion of CD3 + CD19 + double positive cells in peripheral blood through flow cytometry, and comparing the proportion with a proportion threshold in a positive judgment standard for judgment; when the detection result is greater than or equal to 0.20%, judging that the sample is positive; cD3 + CD19 + double positive cells exist in B-ALL peripheral blood, the detection rate of B-ALL peripheral blood in peripheral blood of healthy people and other types of leukemia patients is extremely low, and the B-ALL has high specificity; compared with bone marrow puncture and other invasive diagnosis methods, the non-invasive primary screening of B-ALL is realized, and the problem of insufficient specificity of the existing non-invasive detection technology is overcome; the kit is suitable for early screening of children B-ALL, dynamic monitoring of chemotherapy curative effect and prognosis evaluation, and has important clinical application value.

The invention relates to the field of biomedical detection. The invention discloses application of a ZNF683 + effect memory CD8T cell as a marker for predicting the curative effect of TNBC chemotherapy and in preparation of a kit for predicting the curative effect of TNBC chemotherapy. Compared with the prior art, the invention discloses that the ZNF683 + CD8T cell is used as the marker for the first time, the kit is prepared, and the chemotherapy curative effect of a patient is predicted by detecting the level of the ZNF683 + CD8T cell in the blood of the TNBC patient before and after treatment. The invention provides a high-reliability, simple and fast way for predicting and evaluating the chemotherapy curative effect of TNBC, especially the curative effect of neoadjuvant chemotherapy.

The invention discloses a breast cancer neoadjuvant chemotherapy result evaluation system, and belongs to the field of medical diagnosis. The breast cancer neoadjuvant chemotherapy result evaluation system comprises a data collection module, a data processing module, a tumor analysis module and a tumor grading module. The problem that stable and reliable chemotherapy curative effect evaluation is lacked in the prior art is solved, the image data before and after chemotherapy are collected and preprocessed, and then the tumor area characteristics in the image data are extracted by using the convolutional neural network model, so that deep analysis and diagnosis of tumors are realized, and the chemotherapy curative effect evaluation accuracy is improved. The characteristics of image data before and after chemotherapy are compared, and the size of the tumor is calculated by utilizing the mahalanobis distance, so that the change rule of the tumor before and after chemotherapy is further disclosed, a basis is provided for formulating a reasonable treatment scheme, the chemotherapy effect is divided into different grades according to an analysis result, and the treatment efficiency is improved. And corresponding treatment schemes are formulated according to different grades so as to improve the treatment effect.

The invention discloses a precise tumor chemoradiotherapy drug delivery device, which relates to the technical field of medical instruments, and comprises an injection host and a high-precision peristaltic pump mounted in the injection host, and further comprises a drug storage mechanism, a movable loosening and clamping assembly and a leakage detection assembly. During use, three independent cabin seats are arranged in the medicine storage mechanism, three medicine storage devices are clamped in the three independent cabin seats respectively, loading of three chemotherapeutic medicines can be completed in advance, frequent replacement of medicine storage cylinders is not needed, ordered infusion of the three medicines is achieved through opening and closing of a controllable communication valve in the gathering pipeline assembly, the treatment time is shortened, infusion continuity is improved, and the treatment efficiency is improved. In addition, in the medicine injection process, all the sensors detect medicine leakage, pipeline blockage, bubbles and medicine stock in real time, and precise medicine conveying is achieved. And a clamping mechanism is arranged in the module cabin body assembly, so that the medicine storage cylinder can be quickly disassembled and assembled, and the operation is simple and convenient.

The invention discloses a research method for promoting glioblastoma drug resistance by regulating YAP through P4HA1, and relates to the technical field of biology. The invention aims at researching whether P4HA1 has hydroxylation on YAP, so that the drug resistance of GBM to TMZ is influenced, and finally the proliferation condition of GBM is influenced, further exploring whether the treatment resistance of GBM can be improved after a P4HA1 inhibitor and a YAP inhibitor are combined with TMZ, and evaluating the possibility that P4HA1 and YAP are used as potential treatment targets by understanding the interaction between P4HA1 and YAP. According to the invention, a new treatment method capable of overcoming the drug resistance of GBM chemotherapy is found, the chemotherapy effect is improved, so that the prognosis of a patient is improved, the influence of P4HA1 and YAP on the drug sensitivity of GBM is innovatively evaluated, a new treatment strategy is provided for overcoming the clinical drug resistance problem, and potential signal channels and molecular targets are found.

The application relates to the field of medicine, in particular to the application of 4-hydroxyphenylacetic acid and irinotecan as cancer chemotherapy drugs. In view of the technical defects that the existing irinotecan chemotherapy hepatoprotective drugs have single action and may interfere with the chemotherapy effect, the application provides the application of 4-hydroxyphenylacetic acid and irinotecan in the preparation of cancer chemotherapy drugs. The application has the following advantages: 1. clear hepatoprotective effect: 4HPAA can significantly alleviate the liver fatty degeneration induced by irinotecan; 2. significant synergistic anti-tumor effect: the tumor inhibition effect of the combination of 4HPAA and irinotecan is significantly better than that of the single-drug group; 3. high safety; and 4. great clinical transformation potential.

This invention discloses a mesoporous silica nanoparticle, its preparation method, pharmaceutical composition, and applications. The nanoparticle is epoxy-modified, with its mesoporous channels loaded with polypeptide precursor molecules grafted onto chemotherapeutic drug molecules. Its outer layer is coated with an acid-sensitive polymer layer, enabling it to trigger drug release in the slightly acidic environment of the tumor. Furthermore, under the catalysis of highly expressed active enzymes within the nanoparticle, in-situ gelation occurs at the lesion site, thereby prolonging the retention time of the nanomedicine, improving the bioavailability of chemotherapeutic drugs, and enhancing the efficacy of chemotherapy.

The embodiment of the invention discloses an osteosarcoma chemotherapy effect-enhancing and toxicity-reducing traditional Chinese medicine composition, a traditional Chinese medicine preparation, a preparation method and application. The osteosarcoma chemotherapy effect-enhancing and toxicity-reducing traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 9 to 30 parts of radix astragali seu hedysari, 9 to 15 parts of radix scrophulariae, 5 to 10 parts of radix cyathulae, 6 to 12 parts of radix angelicae sinensis, 3 to 9 parts of pseudobulbus cremastrae seu pleiones and 9 to 30 parts of herba hedyotidis diffusae. The osteosarcoma chemotherapy efficacy-enhancing and toxicity-reducing traditional Chinese medicine composition provided by the embodiment of the invention consists of astragalus membranaceus, radix scrophulariae, radix cyathulae, angelica sinensis, edible tulip and oldenlandia diffusa, has a good curative effect on osteosarcoma, and can reduce the toxic and side effects of chemotherapeutic drugs on individuals with tumors.